Everolimus 10 mg and pancreatic neuroendocrine tumours: many adverse effects and uncertain benefit.
In a placebo-controlled trial, the median time to radiologic documentation of cancer worsening or death was extended by about 6 months, although patients experienced many, often serious, adverse effects.